(HSIC) Henry Schein - Ratings and Ratios
Dental Merchandise, Medical Supplies, Pharmaceuticals, Equipment, Software
HSIC EPS (Earnings per Share)
HSIC Revenue
Description: HSIC Henry Schein
Henry Schein Inc (NASDAQ:HSIC) is a global provider of healthcare products and services to dental and medical practitioners, operating through three main segments: Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology. The company offers a wide range of products, including dental merchandise, equipment, pharmaceuticals, and consumable merchandise under its own brand.
The companys diverse product portfolio and services, including financial services, education, and consulting, cater to various customers, such as dental practices, laboratories, physician practices, and ambulatory surgery centers. Additionally, Henry Schein develops and distributes practice management software and e-services to healthcare providers. With a history dating back to 1932, the company has established itself as a leading player in the healthcare distribution industry.
From a financial perspective, Henry Schein has demonstrated a relatively stable performance, with a return on equity (ROE) of 11.87%. To further analyze the companys performance, we can examine key performance indicators (KPIs) such as revenue growth, gross margin, and operating margin. For instance, the companys revenue growth has been driven by its ability to expand its product offerings and services, as well as its global presence. Additionally, its gross margin has been influenced by its ability to negotiate favorable prices with suppliers and manage its inventory effectively.
To assess the companys valuation, we can consider metrics such as the price-to-earnings (P/E) ratio and the forward P/E ratio, which are 22.01 and 14.71, respectively. These metrics suggest that Henry Schein is trading at a premium to its earnings, but the forward P/E ratio indicates that the companys earnings are expected to grow in the future. Furthermore, the companys dividend yield and payout ratio can provide insight into its ability to return value to shareholders.
HSIC Stock Overview
| Market Cap in USD | 8,227m |
| Sub-Industry | Health Care Distributors |
| IPO / Inception | 1995-11-03 |
HSIC Stock Ratings
| Growth Rating | -2.65% |
| Fundamental | 56.5% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -16.7% |
| Analyst Rating | 3.50 of 5 |
HSIC Dividends
Currently no dividends paidHSIC Growth Ratios
| Growth Correlation 3m | -58.6% |
| Growth Correlation 12m | -18.6% |
| Growth Correlation 5y | -11.9% |
| CAGR 5y | 0.60% |
| CAGR/Max DD 5y | 0.02 |
| Sharpe Ratio 12m | -0.02 |
| Alpha | -10.51 |
| Beta | 0.341 |
| Volatility | 28.62% |
| Current Volume | 1924.8k |
| Average Volume 20d | 1892.3k |
| Stop Loss | 66.2 (-3.3%) |
| Signal | -1.10 |
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (389.0m TTM) > 0 and > 6% of Revenue (6% = 766.4m TTM) |
| FCFTA 0.03 (>2.0%) and ΔFCFTA -1.35pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 9.68% (prev 11.15%; Δ -1.47pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.05 (>3.0%) and CFO 512.0m > Net Income 389.0m (YES >=105%, WARN >=100%) |
| Net Debt (3.21b) to EBITDA (961.0m) ratio: 3.34 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.41 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (122.6m) change vs 12m ago -4.67% (target <= -2.0% for YES) |
| Gross Margin 30.83% (prev 30.18%; Δ 0.66pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 120.7% (prev 121.8%; Δ -1.07pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 4.66 (EBITDA TTM 961.0m / Interest Expense TTM 142.0m) >= 6 (WARN >= 3) |
Altman Z'' 2.78
| (A) 0.11 = (Total Current Assets 4.24b - Total Current Liabilities 3.01b) / Total Assets 10.91b |
| (B) 0.32 = Retained Earnings (Balance) 3.48b / Total Assets 10.91b |
| (C) 0.06 = EBIT TTM 662.0m / Avg Total Assets 10.58b |
| (D) 0.54 = Book Value of Equity 3.26b / Total Liabilities 6.01b |
| Total Rating: 2.78 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 56.51
| 1. Piotroski 5.50pt = 0.50 |
| 2. FCF Yield 3.20% = 1.60 |
| 3. FCF Margin 2.80% = 0.70 |
| 4. Debt/Equity 0.90 = 2.11 |
| 5. Debt/Ebitda 3.22 = -2.05 |
| 6. ROIC - WACC 2.56% = 3.20 |
| 7. RoE 11.40% = 0.95 |
| 8. Rev. Trend 20.77% = 1.04 |
| 9. Rev. CAGR 2.02% = 0.25 |
| 10. EPS Trend 2.98% = 0.07 |
| 11. EPS CAGR -14.94% = -1.87 |
What is the price of HSIC shares?
Over the past week, the price has changed by +1.86%, over one month by -4.18%, over three months by -7.05% and over the past year by -3.43%.
Is Henry Schein a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of HSIC is around 62.97 USD . This means that HSIC is currently overvalued and has a potential downside of -8.03%.
Is HSIC a buy, sell or hold?
- Strong Buy: 3
- Buy: 4
- Hold: 8
- Sell: 0
- Strong Sell: 1
What are the forecasts/targets for the HSIC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 72.2 | 5.5% |
| Analysts Target Price | 76.4 | 11.5% |
| ValueRay Target Price | 68.3 | -0.2% |
Last update: 2025-08-19 02:48
HSIC Fundamental Data Overview
CCE Cash And Equivalents = 145.0m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 21.8135
P/E Forward = 14.3266
P/S = 0.6441
P/B = 2.3881
P/EG = 1.6854
Beta = 0.817
Revenue TTM = 12.77b USD
EBIT TTM = 662.0m USD
EBITDA TTM = 961.0m USD
Long Term Debt = 2.09b USD (from longTermDebt, last quarter)
Short Term Debt = 1.01b USD (from shortTermDebt, last quarter)
Debt = 3.10b USD (Calculated: Short Term 1.01b + Long Term 2.09b)
Net Debt = 3.21b USD (from netDebt column, last quarter)
Enterprise Value = 11.18b USD (8.23b + Debt 3.10b - CCE 145.0m)
Interest Coverage Ratio = 4.66 (Ebit TTM 662.0m / Interest Expense TTM 142.0m)
FCF Yield = 3.20% (FCF TTM 358.0m / Enterprise Value 11.18b)
FCF Margin = 2.80% (FCF TTM 358.0m / Revenue TTM 12.77b)
Net Margin = 3.05% (Net Income TTM 389.0m / Revenue TTM 12.77b)
Gross Margin = 30.83% ((Revenue TTM 12.77b - Cost of Revenue TTM 8.84b) / Revenue TTM)
Tobins Q-Ratio = 3.43 (Enterprise Value 11.18b / Book Value Of Equity 3.26b)
Interest Expense / Debt = 1.23% (Interest Expense 38.0m / Debt 3.10b)
Taxrate = 24.33% (from yearly Income Tax Expense: 128.0m / 526.0m)
NOPAT = 500.9m (EBIT 662.0m * (1 - 24.33%))
Current Ratio = 1.41 (Total Current Assets 4.24b / Total Current Liabilities 3.01b)
Debt / Equity = 0.90 (Debt 3.10b / last Quarter total Stockholder Equity 3.44b)
Debt / EBITDA = 3.22 (Net Debt 3.21b / EBITDA 961.0m)
Debt / FCF = 8.66 (Debt 3.10b / FCF TTM 358.0m)
Total Stockholder Equity = 3.41b (last 4 quarters mean)
RoA = 3.57% (Net Income 389.0m, Total Assets 10.91b )
RoE = 11.40% (Net Income TTM 389.0m / Total Stockholder Equity 3.41b)
RoCE = 12.03% (Ebit 662.0m / (Equity 3.41b + L.T.Debt 2.09b))
RoIC = 8.10% (NOPAT 500.9m / Invested Capital 6.19b)
WACC = 5.53% (E(8.23b)/V(11.33b) * Re(7.27%)) + (D(3.10b)/V(11.33b) * Rd(1.23%) * (1-Tc(0.24)))
Shares Correlation 5-Years: -100.0 | Cagr: -3.31%
Discount Rate = 7.27% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 75.56% ; FCFE base≈404.8m ; Y1≈342.0m ; Y5≈258.9m
Fair Price DCF = 39.13 (DCF Value 4.75b / Shares Outstanding 121.3m; 5y FCF grow -18.81% → 3.0% )
Revenue Correlation: 20.77 | Revenue CAGR: 2.02%
Rev Growth-of-Growth: 2.93
EPS Correlation: 2.98 | EPS CAGR: -14.94%
EPS Growth-of-Growth: 45.18
Additional Sources for HSIC Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle